This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Houssiau, F. Articles by Ginzler, E. Search for Related Content PubMed PubMed Citation Articles by Houssiau, F. Articles by Ginzler, E. Social Bookmarking                         What's this?

Current treatment of lupus nephritis

Rheumatology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium

EM Ginzler

Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, New York, USA

This review on the management of lupus nephritis is based on the results of randomized clinical trials, and discusses the principles of treatment and the current options for induction and maintenance therapy. The respective place of mycophenolate mofetil and intravenous cyclophosphamide are balanced, taking into account efficacy, safety and patients’ perspective. The authors anticipate that, in a few years, when long-term data on lupus nephritis patients induced with mycophenolate mofetil becomes available, it is probably that intravenous cyclophosphamide, which has been for so long the ‘standard of care’, will be prescribed only in specialized conditions such as documented necrotizing vasculitis.

Lupus, Vol. 17, No. 5, 426-430 (2008)
DOI: 10.1177/0961203308090029


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F A Houssiau, C Vasconcelos, D D'Cruz, G D Sebastiani, E de Ramon Garrido, M G Danieli, D Abramovicz, D Blockmans, A Cauli, H Direskeneli, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide Ann Rheum Dis, January 1, 2010; 69(01): 61 - 64. [Abstract] [Full Text] [PDF]

				Z. Zhang, V. C. Kyttaris, and G. C. Tsokos The Role of IL-23/IL-17 Axis in Lupus Nephritis J. Immunol., September 1, 2009; 183(5): 3160 - 3169. [Abstract] [Full Text] [PDF]

				J. H. M. Berden Azathioprine, the Cinderella in the treatment of lupus nephritis Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2611 - 2612. [Full Text] [PDF]

				J. N. Boletis, S. Marinaki, C. Skalioti, S. S. Lionaki, A. Iniotaki, and P. P. Sfikakis Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2157 - 2160. [Abstract] [Full Text] [PDF]

				M. Kriegel, C Van Beek, A Mostaghimi, and V. Kyttaris Sterile empyematous pleural effusion in a patient with systemic lupus erythematosus: a diagnostic challenge Lupus, June 1, 2009; 18(7): 581 - 585. [Abstract] [PDF]

				C. Melander, M. Sallee, P. Trolliet, S. Candon, X. Belenfant, E. Daugas, P. Remy, V. Zarrouk, E. Pillebout, C. Jacquot, et al. Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 579 - 587. [Abstract] [Full Text] [PDF]